Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Large B-Cell, Diffuse 18Lymphoma, Non-Hodgkin 17Neuroblastoma 16Leukemia, Myeloid, Acute 14Leukemia 13Hodgkin Disease 13Central Nervous System Neoplasms 13Small Cell Lung Carcinoma 10Sarcoma 9Brain Neoplasms 9Recurrence 8Medulloblastoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Rhabdoid Tumor 7Multiple Myeloma 7Lymphoma, B-Cell 7Lung Neoplasms 7Burkitt Lymphoma 7Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 6Astrocytoma 6Teratoma 5Ovarian Neoplasms 5Neoplasms, Germ Cell and Embryonal 5Neoplasms 5Glioma 5

Interventions

Rituximab 4Etoposide 4Cyclophosphamide 4Vincristine 3Prednisone 3Doxorubicin 3liposomal doxorubicin 2varlilumab 1prednylidene 1pomalidomide 1fialuridine 1etoposide phosphate 1deltacortene 1Vorinostat 1Ultrasonography 1Salvia hispanica seed extract 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Endoscopy 1Electrocardiography 1Echocardiography 1Disulfides 1Cytarabine 1Carmustine 1CT-P10 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoma, Primary Effusion × etoposide phosphate × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡